Comparison of Efficacy and Safety between Dienogest and Danazol in Women with Endometriosis

Mst. Amena Khatun, Dr. Most. Salma Akhtar Zahan, Anju Ara Khatun, Mst. Hazera khatun
In: Scholars Journal of Applied Medical Sciences · 2022 · vol. 10(8) , pp. 1400–1409 · doi:10.36347/sjams.2022.v10i08.039 · W4293740569
article OA: diamond CC0
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This randomized trial found both dienogest and danazol significantly improved endometriosis symptoms, with similar post-treatment outcomes for pain, dyspareunia, bleeding patterns, and ovarian endometrioma size.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Background: Endometriosis is a common gynecologic disease associated with a significant burden on women's health and healthcare systems. Currently approved hormonal treatments for Endometriosis can effectively control symptoms but may have clinically relevant side effects that limit their use. Objective: This study aimed to compare the Efficacy and safety of commonly used drugs dienogest and danazol in patients with Endometriosis. Methods and Material: This randomized clinical trial was conducted at the department of Obst and Gynae in Rajshahi Medical College Hospital from June 2020 to May 2021. A total of 100 diagnosed cases of Endometriosis were included in this study according to inclusion and exclusion criteria. The study population was divided into two groups randomly by flipping a coin; group A is the dienogest group (experimental group), and group B is the danazol group (control group). Informed written consent was obtained from all cases. Patients were followed up after 3 months of treatment following a standard management plan. After data collection, data analysis was done using SPSS version 23. Result: Mean age of the study patients was 28.72±4.71 (SD) years in group A and 29.52±5.23 (SD) years in group B patients with a majority in the age group 26-30 years. Age and other socio-demographic variables were statistically similar in both groups. Symptomatic improvement was observed with statistical significance in both groups regarding visual analog scale (VAS) pain score and severity of dyspareunia and bleeding pattern according to pictorial blood loss assessment chart (PBAC) score (p.05). Pre-treatment size of ovarian endometrioma was 4.02±0.227 cm (SD) in group A patients and 3.98±0.212 cm (SD) in group B patients. After treatment, ovarian endometrioma significantly (p<.05) reduced to 1.33±0.698 cm (SD) in group A and 1.47±0.967 cm ......

My notes (saved in your browser only)

Outcome instruments

VAS-pain

Condition tags

endometriosisendometriomadyspareunia

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (24)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK